Multiple myeloma treatment in the Philippines has seen significant advancements over the last two decades, including the use of proteasome inhibitors and immunotherapy. Despite these improvements, financial accessibility remains a major issue, with many patients relying on basic therapies. The number of trained hematologists is increasing, and efforts are underway to secure government insurance coverage. Immunotherapy shows promise for better survival rates, and collaboration with stakeholders is crucial for patient support.

AI has been used for both descriptions and subtitles, even though it has been checked, there may be errors.